CorMedix to Acquire Heron Therapeutics Assets for $145 Million and 14.6 Million Shares
CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets for $145 million in cash, subject to adjustments, and 14,583,333 CorMedix shares. The deal also includes potential royalties and up to $55 million in ZYNRELEF earn-outs, and requires Heron stockholder approval.
Story updates
01:04:12 PM UTC
SquawkNews
By Kelly CloonanCorMedix Therapeutics agreed to acquire substantially all of Heron Therapeutics' assets, and assume some of Heron's liabilities, in a deal that adds four commercial-stage products to its portfolio.Under the agreement, CorMedix will pay upfront consideration of $145 million in cash a…
CorMedix agreed to acquire substantially all of Heron Therapeutics' assets for $145 million in cash, subject to adjustments, and 14,583,333 CorMedix shares, with additional potential royalties and up to $55 million in ZYNRELEF earn-outs. The proposed acquisition requires Heron stockholder approval…